Enterome announces presentation of data from ongoing Phase 2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022

EO2401 is a first-in-class OncoMimics™ peptide-based immunotherapy able to rapidly activate and significantly expand existing effector memory CD8+ T cells against tumor-associated driver antigens due to their strong cross-reactivity with OncoMimics™ peptides Paris, France – November 16, 2022 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces it will present updated efficacy, immunogenicity and safety data from its Phase 2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (ROSALIE trial) in an oral presentation at the 27th Society for Neuro-Oncology (SNO) Annual Meeting which will be held in Tampa Bay, Florida, US on November 16-20, 2022. Oral Presentation Details – Abstract CTIM-17 Title: EO2401 therapeutic vaccine for patients with recurrent glioblastoma: phase 1/2 ROSALIE study (NCT04116658) Authors: D. Reardon et al . Date: November 18, 2022, 4:35 pm EST Location: Tampa Convention Center, Ballroom B Presenter: Prof. David Reardon, M.D., Professor of Medicine at Harvard Medical School, and Clinical Director for Dana Farber Cancer Institute Link to abstract published in a supplement to Neuro-Oncology , the Official Journal of the Society for Neuro-Oncology can be found here , and the presentation will be available on Enterome’s website . About EO2401 EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics™ peptide-based immunotherapy. It combines three microbial-derived OncoMimics™ peptides that closely mimic specific cytotoxic T cell (CD8+ T cell) epitopes on the Tumor-Associated Antigens IL13Ra2, BIRC5 and FOXM1, combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2). EO2041 is designed to trigger the immune system into recognizing these epitopes on glioblastoma cells as foreign (non-self) and eliciting a targeted memory T-cell driven cell-killing response against the tumor cells. Promising data presented during 2022 at ASCO, ESMO, EANO and SITC Data confirm that EO2401 in combination with nivolumab +/- bevacizumab is well tolerated with a safety profile consistent with the safety profiles of nivolumab and bevacizumab, with the addition of local administration site reactions. EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with efficacy. Addition of bevacizumab, either as a low-dose symptom driven time-limited treatment, or as a continuous treatment at the labelled US dose, to EO2401 in combination with nivolumab supported longer treatment durations and an increase in efficacy. CD8+ T cells against at least one of the EO2401 peptides was detected in 26 out of 28 patients with some patients exhibiting up to 5% of circulating specific CD8+ T cells. Memory specific CD8+ T cells response were found as early as two weeks after the first vaccination and maintenance of a strong and stable immune response could be detected for more than 10 months. Additional patients are to be treated with triple combination of EO2401/nivolumab/bevacizumab to support final regimen selection for further studies. About ROSALIE ROSALIE (EOGBM1-18, NCT04116658) is a multicenter, open-label, Phase 1/2 trial investigating EO2401 in combination with nivolumab, and in combination with nivolumab/bevacizumab in patients with glioblastoma at first progression/recurrence after surgery and adjuvant radiotherapy/temozolomide. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe. Download the press release (.pdf format) Enterome Headquarters 94/96 avenue Ledru-Rollin 75011 Paris – France Tel: +33 (0)1 75 77 27 85 Email: [email protected] Metro Station: Ledru-Rollin (Line 8) About About us Leadership Investors Pipeline Pipeline OncoMimics™ Platform Our Mimicry Approach Our Drug Discovery Platform Clinical Trials B cell malignancies Glioblastoma Adrenal tumors Colorectal Cancer News & Events Press Releases Press Coverage Webinars Presentations & Posters Relevant Literature Careers Our Values Careers Cookies Policy Privacy Policy Legal Notice

The release as fetched from its publisher. enterome.com ↗